An observational study in Mild Cognitive Impairment, Alzheimer's Disease and Alzheimer's Disease Dementia, sponsored by Getúlio Vargas University Hospital. Recruiting at 1 site in Brazil. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Getúlio Vargas University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Cognitive Dysfunction with a site in Brazil — 10 open to participants now, 14 under way, 6 of them phase 3. Cognitive Dysfunction · Brazil.
Among the 40 studies in Cognitive Dysfunction with a site in Brazil, this one is one of 5 that started in 2026, is one of 6 observational ones, reaches primary completion later than 4 of the 13 other live ones, and was the 38th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →10 of the 40 studies in Cognitive Dysfunction with a site in Brazil are open now. Recruiting first, the newest first:
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Brazil, Australia, Austria and 14 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Brazil, United States, Argentina and 14 more countries
Ages 60–85
Bristol-Myers Squibb · Sites in Brazil, United States, Argentina and 16 more countries
Ages 60–85
Hoffmann-La Roche · Sites in Brazil, United States, Argentina and 12 more countries
Ages 50–90
Universidade Federal do Rio de Janeiro · Sites in Brazil
Ages 50+ · Healthy volunteers
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 9 · Phase 4 2
First in 2007; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is close to the median of 150 across 1,000 observational studies indexed under Cognitive Dysfunction.
Median enrollment 70 across the 34 interventional studies, 155 across the 6 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 40 have an industry lead sponsor. The 10 most frequent:
Getúlio Vargas University Hospital is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Getúlio Vargas University Hospital has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
4 of the studies in Cognitive Dysfunction with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03263247São Paulo State UniversityCognitive Training in Patients With MCI Using fMRI | 2026-12-31 |
| NCT06733714Universidade Federal do Rio de JaneiroAssociation of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults | 2027-03-01 |
| NCT07391436Getúlio Vargas University HospitalUse of Wearables for Identifying Factors Associated With Mild Cognitive Impairment and Early-Stage Alzheimer's Disease | 2027-07 |
| NCT07731529Federal University of Rio Grande do SulVivifrail Exercise Program in Nonagenarians: Effects on Function, Muscle, and Cognition | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies in Cognitive Dysfunction with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cognitive decline affects millions of older adults worldwide and has a profound impact on individuals, families, and healthcare systems. Mild Cognitive Impairment (MCI) is often an early stage of Alzheimer's disease (AD), a condition for which there is currently no cure. Identifying individuals at risk at the earliest possible stage remains a major challenge. Traditional diagnostic approaches, such as laboratory biomarkers, neuroimaging, and neuropsychological testing, are usually performed at a single point in time and may fail to detect subtle or early changes in brain function and daily behavior.
Recent advances in wearable technology, such as smartwatches and smart rings, allow continuous and noninvasive monitoring of physiological and behavioral patterns in daily life. These devices can capture data related to physical activity, sleep, heart rate, and other parameters that may change before clear cognitive symptoms become evident. When combined with clinical, laboratory, neuropsychological, neuroimaging, and electroencephalographic (EEG) information, these data may help identify early signs of cognitive decline.
The objective of this study is to develop and validate models capable of detecting early indicators of MCI and early-stage Alzheimer's disease by integrating multiple sources of data, including clinical assessments, blood tests, neuropsychological evaluations, brain imaging, EEG recordings, and continuous data obtained from wearable devices.
This is an observational, analytical, single-center, prospective cohort study that will include 150 participants of both sexes, aged 65 years or older. Participants will be recruited from the Dementia Outpatient Clinic of Getúlio Vargas University Hospital (HUGV), through referrals from external neurologists, or via study dissemination on social media. To achieve the target sample size, up to 250 individuals may be approached using a non-probabilistic, convenience-based recruitment strategy. After providing informed consent, participants will undergo a comprehensive medical evaluation, standardized and validated neuropsychological testing, laboratory and imaging examinations, and EEG recording. Participants will also receive training to use wearable devices for continuous monitoring in their daily routines. A control group of older adults without cognitive impairment will be included for comparison.
All collected data will be securely stored in a centralized database and used to develop and validate analytical models aimed at identifying patterns associated with cognitive decline. The results of this study may support earlier identification of individuals at risk for MCI and Alzheimer's disease, help guide timely interventions, and potentially delay disease progression and early institutionalization, contributing to improved quality of life for older adults and their families.
Mild Cognitive Impairment (MCI) and early-stage Alzheimer's disease (AD) represent critical stages along the continuum of neurodegenerative cognitive disorders. Understanding these conditions is essential for enabling early diagnosis, implementing targeted therapeutic strategies, and developing comprehensive care plans aimed at improving patient and caregiver quality of life and, when possible, delaying neurodegenerative progression.
The global burden of dementia is rapidly increasing and poses an urgent public health challenge. Projections estimate that approximately 115 million people worldwide will be living with dementia by 2050. In the United States alone, the prevalence of MCI is expected to exceed 21 million individuals, with nearly 14 million cases of Alzheimer's disease by 2060. These figures highlight the pressing need for advances in translational neuroscience, particularly in early diagnostic strategies and preventive, personalized approaches to care.
In this context, wearable technologies have emerged as promising tools for continuous, noninvasive monitoring of physiological and behavioral parameters in real-world settings. Devices such as smartwatches and smart rings enable longitudinal collection of data related to heart rate variability, sleep architecture, physical activity, and circadian rhythms-factors increasingly associated with cognitive decline. Emerging evidence suggests that changes in these parameters may precede or accompany early cognitive impairment. When integrated with advanced artificial intelligence (AI) methods, these data may reveal subtle patterns indicative of early neurodegenerative processes that precede overt clinical symptoms.
Combining wearable-derived data with neuroimaging and electroencephalography (EEG) has the potential to generate more robust diagnostic models. While wearables capture behavioral and physiological dynamics, magnetic resonance imaging (MRI) provides detailed information on brain structure and function, and EEG enables analysis of neural oscillations and connectivity patterns linked to early cognitive impairment. The integration of these multimodal data streams represents a complex methodological challenge, requiring advanced computational frameworks capable of handling heterogeneous, high-dimensional datasets.
Advances in artificial intelligence and machine learning enable the integration of multimodal data and the identification of complex patterns not detectable through traditional analytical approaches. Multimodal data fusion strategies that combine wearable-derived physiological and behavioral features with neuropsychological, neuroimaging, and EEG-derived variables may enhance diagnostic performance and support individualized risk stratification.
This is an observational, analytical, single-center, prospective cohort study designed to integrate multimodal clinical and digital data for the development and validation of AI-based models aimed at early detection of MCI and early-stage Alzheimer's disease. The study is conducted at Getúlio Vargas University Hospital (HUGV), a tertiary academic center and regional reference for high-complexity care, in collaboration with the Center for Research and Development in Electronic and Information Technology (CETELI/UFAM), which provides expertise in intelligent systems, data infrastructure, and AI model development.
Machine learning and deep learning approaches are applied to identify patterns associated with cognitive decline, support early detection of MCI and early AD, and enable risk stratification. Model development and validation prioritize robustness, interpretability, and potential clinical applicability.
This study aims to support the development of scalable, accessible, and noninvasive AI-based tools for early detection of cognitive impairment. By leveraging continuous wearable monitoring and multimodal data integration, the proposed approach may contribute to earlier diagnosis, improved risk stratification, and more timely intervention strategies for individuals at risk of Alzheimer's disease.
Participants will be identified primarily at the Dementia Clinic of the Araújo Lima Outpatient Clinic while waiting to see a neurologist. A clinical screening will be conducted by trained nurses to verify the presence of characteristics compatible with the eligibility criteria according to CRF02 Eligibility. In addition to these patients, individuals referred by physicians not affiliated with HUGV or who directly seek out the Clinical Research Center (CPC/HUGV) after learning about the study through social media, institutional publications, or news reports may also undergo the same pre-screening. Patients who meet the inclusion criteria will initially be invited to a presentation on the objectives, procedures, risks, and benefits of participating in the project. If they agree to participate voluntarily in the project, they will be presented with the Informed Consent Form (ICF) for subsequent signature, in accordance with current ethical guidelines.
Inclusion criteria Age 65 years or older; Clinical suspicion of MCI, early AD Patients who are conscious, oriented, and able to respond to questionnaires; Ability and willingness to use wearable devices for 30 days; Signature of the Form (ICF)
Non-inclusion criteria Advanced dementia Severe uncontrolled psychiatric disorder Severe visual or hearing impairment that prevents communication Severe physical or cognitive inability to use wearables Pacemaker incompatible with the devices
Exclusion criteria Unconfirmed diagnosis of MCI or early AD; Voluntary withdrawal at any stage of the study; Death during the research period; Inappropriate use or non-adherence to the use of wearable devices Refusal or inability to fully perform the requested tests and exams.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals without significant abnormalities on imaging exams, biomarkers, or neuropsychological assessment.
Participants with abnormalities in cognitive questionnaire scores and/or laboratory biomarkers, but without significant functional impairment.
Individuals with altered laboratory and/or imaging results compatible with the initial phase of neurodegeneration.
Accuracy of a Predictive Model for Identification of Mild Cognitive Impairment and Early Alzheimer's Disease
Evaluation of the accuracy, defined as the proportion of correctly classified participant, of a predictive model developed to identify Mild Cognitive Impairment and early-stage Alzheimer's Disease based on data collected from wearable technologies and digital questionnaires, using established clinical and standardized neuropsychological diagnoses as the reference standard.
Time frame: Up to 30 days of continuous wearable monitoring
Association Between Speech and Voice Features From Smartphone Audio and Clinical Group
Evaluation of the relationship between speech and voice features extracted from smartphone-based audio recordings including speech rate articulation pause patterns pitch variability and voice quality measures and clinical group classification control, mild cognitive impairment, and early Alzheimer's disease, including correlations with cognitive and functional scores.
Time frame: Up to 30 days
Association Between Wearable-Derived Sleep Metrics and Clinical Group
Evaluation of the association between wearable-derived sleep parameters including total sleep time, sleep efficiency, sleep latency, wake after sleep onset, and sleep stage distribution and clinical group classification cognitively unimpaired control, mild cognitive impairment, and early Alzheimer's disease, as well as correlations between sleep metrics and standardized cognitive and functional assessment scores.
Time frame: Up to 30 days
Association Between Wearable-Derived Physical Activity Metrics and Clinical Group
Assessment of the relationship between wearable-derived physical activity metrics including daily step count, activity intensity levels, sedentary time, and energy expenditure and clinical group classification control, mild cognitive impairment, and early Alzheimer's disease, including correlations with cognitive and functional performance measures.
Time frame: Up to 30 days
Association Between Wearable-Derived Heart Rate and Heart Rate Variability Metrics and Clinical Group
Analysis of the association between wearable-derived heart rate and heart rate variability parameters including resting heart rate and time-domain and frequency-domain HRV indices and clinical group classification control, mild cognitive impairment, and early Alzheimer's disease, as well as correlations with cognitive and functional scores
Time frame: Up to 30 days
Difference in Timed Up and Go Performance Across Clinical Groups
Comparison of Timed Up and Go test performance across clinical groups control, mild cognitive impairment, and early Alzheimer's disease and evaluation of correlations between TUG performance and wearable-derived physical activity and sleep metrics.
Time frame: Baseline assessment Day 1 (up to 30 days)
Association Between Facial Expression Features From Smartphone Video and Clinical Group
Assessment of the association between facial expression features extracted from smartphone-based video recordings including facial action units emotional expressivity and movement dynamics and clinical group classification control, mild cognitive impairment, and early Alzheimer's disease.
Time frame: Up to 30 days
Association Between Smartphone-Derived Eye Movement Features and Clinical Group
Assessment of the association between eye movement and ocular tracking features derived from smartphone-based assessments including saccade metrics fixation stability and pursuit performance and clinical group classification control, mild cognitive impairment, and early Alzheimer's disease.
Time frame: Up to 30 days
Association Between Electroencephalography (EEG) Classification and Clinical Group
Evaluation of the association between electroencephalography classification normal versus abnormal and type of abnormality and clinical group classification control, mild cognitive impairment, and early Alzheimer's disease, as well as correlations between EEG findings and wearable-derived sleep and physical activity metrics.
Time frame: Up to 30 days
Association Between Non-Invasive Intracranial Compliance Metrics and Clinical Group
Assessment of the relationship between non-invasive intracranial compliance metrics obtained using the Brain4Care device including P2 P1 ratio and waveform morphology and clinical group classification control, mild cognitive impairment, and early Alzheimer's disease, including correlations with wearable-derived sleep and physical activity metrics.
Time frame: Up to 30 days
Association Between Carotid and Vertebral Doppler Findings and Clinical Group
Evaluation of the association between carotid and vertebral Doppler ultrasound findings including intima-media thickness and presence or degree of arterial stenosis and clinical group classification control, mild cognitive impairment, and early Alzheimer's disease.
Time frame: Up to 30 days
Feasibility and Adherence to Continuous Wearable Monitoring
Assessment of feasibility and participant adherence to continuous wearable monitoring, including the percentage of days with valid wearable data, average daily wear time, and study dropout rate.
Time frame: Up to 30 days
Association Between Cognitive and Neuropsychological Performance and Clinical Group
Evaluation of the relationship between global and domain-specific cognitive and neuropsychological performance, including screening measures and standardized neuropsychological tests assessing memory, executive function, attention, language, processing speed, and visuospatial abilities, and clinical group classification control, mild cognitive impairment, and early Alzheimer's disease.
Time frame: Up to 30 days
Association Between Functional, Neuropsychiatric, and Behavioral Measures and Clinical Group
Assessment of the association between functional capacity, neuropsychiatric symptoms, and behavioral measures, including instrumental activities of daily living, anxiety, and depressive symptoms, and clinical group classification control, mild cognitive impairment, and early Alzheimer's disease, including correlations with cognitive and digital biomarkers.
Time frame: Up to 30 days
Association Between Blood-Based Biomarkers and Clinical Group
Evaluation of the relationship between blood-based biomarkers, including routine laboratory parameters and plasma biomarkers of Alzheimer's disease pathology, and clinical group classification control, mild cognitive impairment, and early Alzheimer's disease, including correlations with cognitive, functional, and neuroimaging measures.
Time frame: Up to 30 days
Association Between Neurophysiological Measures and Clinical Group
Assessment of the association between neurophysiological features, including electroencephalographic patterns and noninvasive intracranial compliance waveform metrics, and clinical group classification control, mild cognitive impairment, and early Alzheimer's disease, including correlations with cognitive and neuroimaging outcomes.
Time frame: Up to 30 days
Association Between Neuroimaging Features and Clinical Group
Evaluation of the relationship between structural neuroimaging and cerebrovascular features, including cortical and medial temporal atrophy, white matter disease, microbleeds, infarcts, volumetric and cortical thickness measures, and clinical group classification control, mild cognitive impairment, and early Alzheimer's disease.
Time frame: Up to 30 days
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Jul 2027, 16 months after the start.
Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 16 months is below that.
Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Getúlio Vargas University Hospital